BridgeBio Pharma, Inc.
DE ˙ MUN ˙ US10806X1028
56,19 € ↓ -1,02 (-1,78%)
2026-06-01
AKTIENPREIS
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership746,483 shares
Latest Disclosed Value $ 55,433,827
Citigroup Inc ownership in 2CL / BridgeBio Pharma, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 746,483 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $46,908,992 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 700,251 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 6.60% during the quarter. The current value of the position is $41,944,880 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (2CL) in the form of stock options. The firm currently holds call options representing 45,000 of underlying shares valued at $3,341,700 USD and put options representing 181,000 of underlying shares valued at $13,441,060 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:2CL / BridgeBio Pharma, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 746,483 46,232 6.60 55,434 3.49 0.0236
2026-02-13 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 700,251 -227,700 -24.54 53,562 11.13 0.0236
2025-11-10 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 927,951 -320,554 -25.68 48,198 -10.60 0.0215
2025-08-11 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,248,505 -153,008 -10.92 53,910 11.27 0.0265
2025-05-12 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,401,513 -137,219 -8.92 48,450 14.75 0.0248
2025-02-12 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,538,732 929 0.06 42,223 7.84 0.0250
2024-11-12 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,537,803 222,464 16.91 39,152 17.51 0.0227
2024-08-12 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,315,339 -474,731 -26.52 33,318 -39.80 0.0213
2024-05-10 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,790,070 232,839 14.95 55,349 -11.96 0.0364
2024-02-09 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,557,231 -30,361 -1.91 62,865 50.16 0.0443
2023-12-06 2023-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,587,592 160,076 11.21 41,865 70.50 0.0313
2023-11-09 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,587,592 160,076 41,865 0.0125
2023-08-10 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,427,516 -119,529 -7.73 24,553 -4.28 0.0161
2023-05-11 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,547,045 162,116 11.71 25,650 143.06 0.0180
2023-02-09 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,384,929 -135,132 -8.89 10,553 -30.15 0.0084
2022-11-10 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,520,061 45,659 3.10 15,109 12.86 0.0108
2022-08-10 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,474,402 343,362 30.36 13,387 16.61 0.0100
2022-05-12 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,131,040 -81,298 -6.71 11,480 -43.23 0.0070
2022-02-10 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,212,338 735,295 154.14 20,222 -9.56 0.0108
2021-11-10 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 477,043 -152,317 -24.20 22,359 -41.72 0.0132
2021-08-10 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 629,360 25,960 4.30 38,366 3.22 0.0231
2021-05-13 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 603,400 63,047 11.67 37,169 -3.27 0.0240
2021-02-11 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 540,353 -186,055 -25.61 38,424 40.98 0.0227
2020-11-12 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 726,408 -84,405 -10.41 27,255 3.08 0.0178
2020-08-12 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 810,813 693,775 592.78 26,441 679.05 0.0206
2020-05-12 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 117,038 92,075 368.85 3,394 288.33 0.0031
2020-02-12 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 24,963 23,959 2,386.35 874 4,061.90 0.0006
2019-11-08 2019-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,004 1,004 21 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F BRIDGEBIO PHARMA COM Call 45,000 -7.22 3,342 -9.92 n/a n/a n/a
2026-02-13 2025-12-31 13F BRIDGEBIO PHARMA COM Call 48,500 0.00 3,710 47.24 n/a n/a n/a
2025-11-10 2025-09-30 13F BRIDGEBIO PHARMA COM Call 48,500 -59.92 2,519 -51.78 n/a n/a n/a
2025-08-11 2025-06-30 13F BRIDGEBIO PHARMA COM Call 121,000 -43.83 5,225 -29.84 n/a n/a n/a
2025-05-12 2025-03-31 13F BRIDGEBIO PHARMA COM Call 215,400 31.34 7,446 65.47 n/a n/a n/a
2025-02-12 2024-12-31 13F BRIDGEBIO PHARMA COM Call 164,000 507.41 4,500 555.02 n/a n/a n/a
2024-11-12 2024-09-30 13F BRIDGEBIO PHARMA COM Call 27,000 0.00 687 0.59 n/a n/a n/a
2024-08-12 2024-06-30 13F BRIDGEBIO PHARMA COM Call 27,000 -59.64 684 -66.97 n/a n/a n/a
2024-05-10 2024-03-31 13F BRIDGEBIO PHARMA COM Call 66,900 17.57 2,069 -9.97 n/a n/a n/a
2024-02-09 2023-12-31 13F BRIDGEBIO PHARMA COM Call 56,900 100.35 2,297 207.09 n/a n/a n/a
2023-12-06 2023-09-30 13F/A BRIDGEBIO PHARMA COM Call 28,400 25.11 749 91.79 n/a n/a n/a
2023-11-09 2023-09-30 13F BRIDGEBIO PHARMA COM Call 28,400 749 n/a n/a n/a
2023-08-10 2023-06-30 13F BRIDGEBIO PHARMA COM Call 22,700 0.00 390 3.72 n/a n/a n/a
2023-05-11 2023-03-31 13F BRIDGEBIO PHARMA COM Call 22,700 376 n/a n/a n/a
2023-02-09 2022-12-31 13F BRIDGEBIO PHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-10 2022-09-30 13F BRIDGEBIO PHARMA COM Call 39,100 389 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F BRIDGEBIO PHARMA COM Put 181,000 13,441 n/a n/a n/a
2025-05-12 2025-03-31 13F BRIDGEBIO PHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-12 2024-12-31 13F BRIDGEBIO PHARMA COM Put 40,000 1,098 n/a n/a n/a
2024-08-12 2024-06-30 13F BRIDGEBIO PHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-10 2024-03-31 13F BRIDGEBIO PHARMA COM Put 29,900 0.00 925 -23.45 n/a n/a n/a
2024-02-09 2023-12-31 13F BRIDGEBIO PHARMA COM Put 29,900 5.28 1,207 61.36 n/a n/a n/a
2023-12-06 2023-09-30 13F/A BRIDGEBIO PHARMA COM Put 28,400 749 n/a n/a n/a
2023-11-09 2023-09-30 13F BRIDGEBIO PHARMA COM Put 28,400 749 n/a n/a n/a
2023-02-09 2022-12-31 13F BRIDGEBIO PHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-10 2022-09-30 13F BRIDGEBIO PHARMA COM Put 39,100 389 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.